Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.

IF 3.7 3区医学 Q2 ONCOLOGY

Cancer Epidemiology Biomarkers & Prevention Pub Date : 2025-04-04 DOI:10.1158/1055-9965.EPI-24-1421

Jordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, Kosj Yamoah, Alex C Soupir, Jonathan V Nguyen, Carlos Moran Segura, Adam M Spivak, Beatrice S Knudsen, Qin Zhou, Siwen Hu-Lieskovan, Sonam Puri, Wei Zhang, Yoko S DeRose, Gita Suneja, Anna E Coghill

{"title":"Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.","authors":"Jordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, Kosj Yamoah, Alex C Soupir, Jonathan V Nguyen, Carlos Moran Segura, Adam M Spivak, Beatrice S Knudsen, Qin Zhou, Siwen Hu-Lieskovan, Sonam Puri, Wei Zhang, Yoko S DeRose, Gita Suneja, Anna E Coghill","doi":"10.1158/1055-9965.EPI-24-1421","DOIUrl":null,"url":null,"abstract":"Background: Cancer outcomes in people living with HIV (PWH) may be driven in part by a distinct tumor microenvironment (TME) for tumors that develop in the setting of persistent immune dysfunction.Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without HIV.Results: A total of 292 samples were analyzed, 51 from PWH (lung cancer=17; breast cancer=14; prostate cancer=20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer (OR 1.88; 95% CI: 1.02-3.45), while CD11b+ cells were observed less frequently (OR 0.4; 95% CI: 0.17-0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PDL-1 (OR 3.24; 95% CI: 1.52-6.91), CD14 (OR 3.37; 95% CI: 1.14-10.0), and FOXP3 (OR 1.91; 95% CI: 1.03-3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PDL-1 (OR 5.94; 95% CI: 3.77-9.34); while 3 three markers had lower abundance including CD14 (OR 0.40; 95% CI: 0.22-0.74), as well as CD16 and CD11c.Conclusions: This pilot study showed that differences in the tumor immune microenvironment (TME) exist for PWH diagnosed with age-related NADCs compared to non-infected controls. Future work evaluating TME differences with related clinical endpoints is needed.Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-1421","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer outcomes in people living with HIV (PWH) may be driven in part by a distinct tumor microenvironment (TME) for tumors that develop in the setting of persistent immune dysfunction.

Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without HIV.

Results: A total of 292 samples were analyzed, 51 from PWH (lung cancer=17; breast cancer=14; prostate cancer=20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer (OR 1.88; 95% CI: 1.02-3.45), while CD11b+ cells were observed less frequently (OR 0.4; 95% CI: 0.17-0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PDL-1 (OR 3.24; 95% CI: 1.52-6.91), CD14 (OR 3.37; 95% CI: 1.14-10.0), and FOXP3 (OR 1.91; 95% CI: 1.03-3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PDL-1 (OR 5.94; 95% CI: 3.77-9.34); while 3 three markers had lower abundance including CD14 (OR 0.40; 95% CI: 0.22-0.74), as well as CD16 and CD11c.

Conclusions: This pilot study showed that differences in the tumor immune microenvironment (TME) exist for PWH diagnosed with age-related NADCs compared to non-infected controls. Future work evaluating TME differences with related clinical endpoints is needed.

Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.

查看原文本刊更多论文

人类免疫缺陷病毒在肺癌、乳腺癌和前列腺癌肿瘤免疫微环境中的相关差异

背景：艾滋病病毒感染者（PWH）的癌症预后可能部分受到在持续免疫功能障碍情况下发生的肿瘤微环境（TME）的影响：艾滋病病毒感染者（PWH）的癌症预后可能部分受肿瘤微环境（TME）的影响，肿瘤是在持续免疫功能障碍的情况下发生的：方法：从艾滋病癌症标本资源、莫菲特癌症中心和亨斯迈癌症研究所回顾性地获得了PWH的肿瘤样本。对PWH患者和癌症患者以及确诊为同一癌症类型但未感染HIV的患者的22种不同肿瘤免疫标记物的染色进行了比较：共分析了 292 份样本，其中 51 份来自 PWH（肺癌 17 份；乳腺癌 14 份；前列腺癌 20 份）。PD-1阳性细胞在PWH和肺癌中出现的频率更高（OR 1.88；95% CI：1.02-3.45），而CD11b+细胞出现的频率较低（OR 0.4；95% CI：0.17-0.93）。三种免疫标记物在PWH和乳腺癌中的丰度较高，包括PDL-1（OR 3.24；95% CI：1.52-6.91）、CD14（OR 3.37；95% CI：1.14-10.0）和FOXP3（OR 1.91；95% CI：1.03-3.53）。在PWH和前列腺癌中，五种免疫标记物的丰度较高，包括PDL-1（OR 5.94；95% CI：3.77-9.34）；而三种标记物的丰度较低，包括CD14（OR 0.40；95% CI：0.22-0.74）以及CD16和CD11c：这项试验性研究表明，与非感染对照组相比，确诊为老年相关性非淋巴细胞白血病的威利人的肿瘤免疫微环境（TME）存在差异。今后需要开展工作，评估肿瘤免疫微环境与相关临床终点之间的差异：影响：研究结果与在免疫抑制环境中发展的癌症的肿瘤发生发生改变的假设一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.50

自引率

2.60%

发文量

538

审稿时长

1.6 months

期刊介绍： Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.